RESP301

DRUG4 trials

Sponsors

University of Birmingham, Thirty Respiratory Limited, Papworth Hospital NHS Foundation Trust

Conditions

BronchiectasisCOPDCOVIDCystic FibrosisPulmonary Complications in Surgical PatientsRifampicin Susceptible Pulmonary TuberculosisSevere Acute Respiratory Syndrome

Phase 2

COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2

TerminatedNCT04858451

Thirty Respiratory LimitedBronchiectasis, COPD

Start: 2021-03-01End: 2023-02-08Updated: 2025-01-31

Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus

TerminatedNCT05101915

Papworth Hospital NHS Foundation TrustCystic Fibrosis

Start: 2021-11-01End: 2024-04-23Updated: 2024-05-10

Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis

TerminatedNCT06041919

Thirty Respiratory LimitedRifampicin Susceptible Pulmonary Tuberculosis

Start: 2023-09-27End: 2025-03-06Updated: 2025-07-15

Phase 3

Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19

SuspendedNCT04386070

University of BirminghamCOVID, Pulmonary Complications in Surgical Patients, Severe Acute Respiratory Syndrome

Start: 2022-05-16End: 2027-03-01Target: 6400Updated: 2025-02-20